Amwill Healthcare IPO Overview

Amwill Healthcare IPO is a book built issue of Rs 59.98 crores. The issue is a combination of fresh issue of 44.04 lakh shares aggregating to Rs 48.88 crores and offer for sale of 10.00 lakh shares aggregating to Rs 11.10 crores.

Amwill Healthcare IPO opens for subscription on February 5, 2025 and closes on February 7, 2025. The allotment for the Amwill Healthcare IPO is expected to be finalized on Monday, February 10, 2025. Amwill Healthcare IPO will list on BSE SME with tentative listing date fixed as Wednesday, February 12, 2025.

Amwill Healthcare IPO price band is set at ₹105 to ₹111 per share. The minimum lot size for an application is 1200. The minimum amount of investment required by retail investors is ₹1,33,200. The minimum lot size investment for HNI is 2 lots (2,400 shares) amounting to ₹2,66,400.

Unistone Capital Pvt Ltd is the book running lead manager of the Amwill Healthcare IPO, while Bigshare Services Pvt Ltd is the registrar for the issue.The market maker for Amwill Healthcare IPO is Globalworth Securities Limited.

Refer to Amwill Healthcare IPO DRHP for detailed information.

Amwill Healthcare IPO Important dates

Amwill Healthcare IPO opens on February 5, 2025, and closes on February 7, 2025.

IPO Open Date Wednesday, February 5, 2025
IPO Close Date Friday, February 7, 2025
Basis of Allotment Monday, February 10, 2025
Initiation of Refunds Tuesday, February 11, 2025
Credit of Shares to Demat Tuesday, February 11, 2025
Listing Date Wednesday, February 12, 2025
Cut-off time for UPI mandate confirmation 5 PM on February 7, 2025

Amwill Healthcare IPO Financial Performance

Period Ended 31 Dec 2023 31 Mar 2023 31 Mar 2022 31 Mar 2021
Assets 20.14 12.39 6.59 8.29
Revenue 36.05 30.28 27.62 18
Profit After Tax 11 3.11 2.57 -1
Net Worth 15.63 4.6 1.49 -1.09
Reserves and Surplus 15.58 4.57 1.46 -1.12
Amount in ₹ Crore

Amwill Healthcare IPO Key Performance Indicator

The market capitalization of Amwill Healthcare IPO is Rs 222.04 Cr.

KPI as of Fri, Mar 31, 2023.

Pre IPO Post IPO
EPS (Rs) 2.00 7.33
P/E (x) 55.6 15.13
Note:

  • The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2023 that is available in RHP.
  • The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of December 31, 2023 that is available in RHP.

Amwill Healthcare IPO Objectives

The company proposes to utilize the Net Proceeds in the following manner.

  1. Funding of working capital requirements of the Company
  2. Marketing and brand-building activities
  3. General corporate purposes

Amwill Healthcare IPO Lot Size

Investors can bid for a minimum of 1200 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.

Application Lots Shares Amount
Retail (Min) 1 1200 ₹1,33,200
Retail (Max) 1 1200 ₹1,33,200
HNI (Min) 2 2,400 ₹2,66,400
Lot Size Calculator

Amwill Healthcare IPO Details

IPO Date February 5, 2025 to February 7, 2025
Listing Date [.]
Face Value ₹10 per share
Price Band ₹105 to ₹111 per share
Lot Size 1,200 Shares
Total Issue Size 54,03,600 shares
(aggregating up to ₹59.98 Cr)
Fresh Issue 44,03,600 shares
(aggregating up to ₹ 48.88 Cr)
Offer for Sale 10,00,000 shares of ₹10
(aggregating up to ₹11.10 Cr)
Issue Type Book Built Issue IPO
Listing At BSE SME
Share Holding Pre Issue 1,56,00,000 shares
Share Holding Post Issue 2,00,03,600 shares
Market Maker Portion 2,71,200 shares
Globalworth Securities Limited

Amwill Healthcare IPO Company Overview and Services

Incorporated in August 2017, Amwill Health Care Limited is a derma-cosmetic development firm that collaborates with contract manufacturers, distributors, and third-party product development agencies. This collaboration has enhanced the company’s manufacturing, packaging, and distribution capabilities.

The product portfolio of the Company is divided into two categories, namely,

  1. Development of generic dermatological solutions and
  2. Formulating targeted solutions for dermatological issues.

The company markets its products in Karnataka, Andhra Pradesh, and Telangana, focusing on strengthening its presence before entering new markets to build a customer base.

The company develops products for dermatological disorders, including acne, fungal infections, anti-ageing, histaminic, periorbital hyperpigmentation, scabies, perspiration, trichology and vitiligo.

As of April 30, 2024, the company’s marketing team comprises 31 employees.

As of April 30, 2024, the company has 59 employees on payroll.

Competitive Strength

  • Extensive product portfolio supported by product formulation capabilities
  • Provision of high quality product development through tie-ups with contract manufacturers and prototype developers
  • Well-experienced management team with proven project management and implementation skills
  • Asset-light business model.

Amwill Healthcare IPO SWOT Analysis

Strengths:

  • Specialized Focus: Amwill specializes in the derma-cosmetic segment, which is a growing market with increasing demand for skincare products.
  • Strong Relationships: The company has established strong ties with dermatologists, which helps in product development and ensures effectiveness.
  • Outsourced Manufacturing: By outsourcing manufacturing, Amwill can focus its resources on product development and marketing, leading to greater efficiency.
  • Established Presence: Amwill has a solid market presence in key southern states, providing a foundation for further expansion.

Weaknesses:

  • Limited Operating History: As a relatively young company, Amwill has a shorter track record compared to established players in the industry.
  • Dependence on Third-Party Manufacturers: Reliance on third-party manufacturers can lead to quality control and supply chain risks.
  • Competition: The skincare industry is highly competitive, with many established brands and new entrants.
  • Regulatory Compliance: The pharmaceutical and cosmetic industry is subject to strict regulations, and any compliance issues can impact operations.

Opportunities:

  • Growing Skincare Market: The derma-cosmetic market is expanding rapidly, driven by increasing awareness of skincare and rising disposable incomes.
  • Expansion Potential: Amwill has the opportunity to expand its product portfolio and geographic reach.
  • E-commerce Growth: The increasing popularity of online shopping provides a platform for Amwill to reach a wider customer base.
  • Product Innovation: Developing innovative and effective skincare solutions can give Amwill a competitive edge.

Threats:

  • Economic Downturn: An economic slowdown can impact consumer spending on discretionary items like skincare products.
  • Competition: Intense competition can lead to price wars and reduced margins.
  • Changing Consumer Preferences: Shifts in consumer preferences and trends can impact demand for specific products.
  • Counterfeit Products: The risk of counterfeit products can affect brand reputation and sales.

Amwill Healthcare IPO GMP Details

GMP for Amwill Healthcare SME IPO has not started yet. We are updating the GMP information on a daily basis. Please visit us again soon for the latest GMP updates.

The GMP for Amwill Healthcare SME IPO has started from 2 session. It is still very early to determine the direction of the GMP. We are updating the information every day, stay tuned with the latest GMP and more details. Stay tuned to learn more about Amwill Healthcare SME IPO daily GMP performance and expected expected listing price.

GMP Date IPO Price GMP Sub2 Sauda Rate Estimated Listing Price Last Updated
01-02-2025 111.00 ₹0  — ₹111 (0.00%) 1-Feb-2025
31-01-2025 111.00 ₹0  — ₹111 (0.00%) 31-Jan-2025

What is IPO GMP?

The grey market premium (GMP) reflects the unofficial trading price of an IPO before its listing, offering insights into its potential market performance. A positive GMP indicates that the IPO may yield profits, while a negative GMP suggests a possible discount upon listing. However, it’s essential to recognize that IPO GMP can be highly volatile. Therefore, investors should not make decisions solely based on the GMP but should thoroughly assess all relevant factors before investing.

Amwill Healthcare IPO Subscription Status 

Note that the bidding starts at 10 AM and ends at 5 PM on the days when the public issue is open.

Amwill Healthcare IPO Allotment status 

Amwill Healthcare IPO allotment is expected on Monday, February 10, 2025.

Amwill Healthcare IPO allotment status is not available at this time. Amwill Healthcare IPO – The allotment status will be available once the basis of allotment is finalized. Please revisit us to check the latest updates for Amwill Healthcare Limited IPO allotment status.

Amwill Healthcare IPO Contact Details

Amwill Healthcare Limited
No. 157, 1st Floor,
2nd Main, r, 2nd Main, 3rd Cross Chamrajpet
Bangalore – 560018
Phone: +91 8043026281
Email: amwill@amwillhealthcare.com
Website: https://www.amwillhealthcare.com/

Disclaimer: Investing in Initial Public Offerings (IPOs) involves substantial risk, and financial returns are not guaranteed. The information provided should not be construed as financial or investment advice. Prospective investors are advised to consider their financial situation, investment objectives, and risk tolerance before participating in an IPO. It is recommended to consult with a qualified financial advisor or professional before making any investment decisions. Past performance is not indicative of future results. Investments in IPOs may be subject to market risk, including the potential loss of principal.

Want to Raise money for your company through SME IPO? Read More